Hämostatische Therapie der intrazerebralen Blutung

E. Jüttler; T. Steiner

doi:10.1055/s-0038-1626868

Nervenheilkunde, Table of Contents

Nervenheilkunde 2007; 26(05): 343-351
DOI: 10.1055/s-0038-1626868

Original Article

Schattauer GmbH

Hämostatische Therapie der intrazerebralen Blutung

Haemostatic therapy for intracerebral haemorrhage

Authors

E. Jüttler

¹Neurologische Universitätsklinik, Universität Heidelberg (Direktor: Prof. Dr. Dipl.-Psych. W. Hacke)
T. Steiner

¹Neurologische Universitätsklinik, Universität Heidelberg (Direktor: Prof. Dr. Dipl.-Psych. W. Hacke)

Abstract

Zusammenfassung

In den letzten Jahren rückte die spontane intrazerebrale Blutung (ICB) mehr und mehr in das Interesse der Schlaganfallforschung und ist dabei, neben der zerebralen Ischämie, einen zweiten Schwerpunkt klinischer Studien zu bilden. Entscheidend hierfür waren unter anderem zwei multizentrische, randomisierte, kontrollierte Therapiestudien, die Anfang 2005 veröffentlicht wurden: Die International Surgical Trial in Intracerebral Haemorrhage (STICH) und die Studie über den rekombinanten aktivierten Faktor VII. Beide beruhen auf der pathophysiologischen Überlegung einer Verbesserung des klinischen Verlaufs durch Verkleinerung des intrazerebralen Hämatoms, entweder durch chirurgische Entfernung oder durch medikamentöse Verminderung des Hämatomwachstums. Wir fassen die wesentlichen ätiologischen und pathophysiologischen Hintergründe der hämostatischen Therapie der ICB zusammen und gehen kurz auf die Antikoagulantien (OAT)-assoziierte ICB ein. Zum Schluss diskutieren wir die Konsequenzen für die zukünftige Therapie und für weitere klinische Studien.

Summary

In recent years, spontaneous intracerebral haemorrhage (ICH) gains more and more interest within stroke research and becomes a major focus of clinical studies. Among others, two multi-centre, randomized, controlled trials were crucial for this development. Both have been published early in 2005: The International Surgical Trial in Intracerebral Haemorrhage (STICH), and the trial investigating recombinant activated factor VII. Both studies are based on the pathophysiological concept of improving the clinical course by reducing the size of the intracerebral haematoma, either by surgical removal or by pharmacological reduction of haematoma growth. We summarize the most important etiologic and pathophysiologic background of haemostatic treatment of ICH and shortly mention oral anticoagulation treatment (OAT)-related ICH. Finally, we discuss the consequences for future therapy and clinical trials.

Schlüsselwörter

Intrazerebrale Blutung - Therapie - klinische Studien

Keywords

Intracerebral haemorrhage - therapy - clinical trials

Full Text

References

Literatur
1 Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003; 34: 2060-2065.
2 Auer LM, Deinsberger W, Niederkorn K, Gell G, Kleinert R, Schneider G, Holzer P, Bone G, Mokry M, Korner E. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg 1989; 70: 530-535.
3 Batjer HH, Reisch JS, Allen BC, Plaizier LJ, Su CJ. Failure of surgery to improve outcome in hypertensive putaminal hemorrhage. A prospective randomized trial. Arch Neurol 1990; 47: 1103-1106.
4 Broderick J, Brott T, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24: 987-993.
5 Broderick J, Brott T, Tomsick T, Leach A. Lobar hemorrhage in the elderly. The undiminishing importance of hypertension. Stroke 1993; 24: 49-51.
6 Broderick JP, Adams HPJr, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D, May-berg M, Tilley B, Zabramski KM, Zuccarello M. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905-915.
7 Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1-5.
8 Butcher KS, Baird T, MacGregor L, Desmond P, Tress B, Davis S. Perihematomal edema in primary intracerebral hemorrhage is plasma derived. Stroke 2004; 35: 1879-1885.
9 Dennis MS. Outcome after brain haemorrhage. Cerebrovasc Dis 2003; 16 (01) 9-13.
10 Diener HC, Outzki N, Berlit P, Hacke W, Hufnagel A, Hufschmidt A, Meier U, Oertel WH, Reichmann H, Rieckmann P, Wallesch CW, Weller M, Schmutzhard E, Mattle H. (Hrsg). Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Georg Thieme Verlag; 2005
11 Diringer MN, Edwards DF, Zazulia AR. Hydrocephalus: a previously unrecognized predictor of poor outcome from supratentorial intracerebral hemorrhage. Stroke 1998; 29: 1352-1357.
12 Erhardtsen E, Nony P, Dechavanne M, French P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ration above 2.0. Blood Coagul Fibrinolysis 1998; 09: 741-748.
13 European Stroke Initiative Writing Committee; Writing Committee for the EUSI Executive Committee. Kaste M, Kwiecinski H, Steiner T, Mendelow D, Juvela S, Marchel A, Unterberg A, Chapot R, Cognard C, Forsting M, Szikora I, Hacke W. Recommendations for the management of intracranial haemorrhage – part I: spontaneous intracerebral haemorrhage. Cerebrovasc Dis 2006; 22: 294-316.
14 Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752.
15 Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059-1064.
16 Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HGJr, Czervionke LF, Meschia JF. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79: 1495-1500.
17 Fuji Y, Tanaka R, Takeuchi S, Koike T, Minakawa T, Sasaki O. Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg 1994; 80: 51-57.
18 Fujitsu K, Muramoto M, Ikeda Y, Inada Y, Kim I, Kuwabara T. Indications for surgical treatment of putaminal hemorrhage. Comparative study based on serial CT and timecourse analysis. J Neurosurg 1990; 73: 518-525.
19 Gebel JMJr, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, Spilker J, Tomsick TA, Duldner J, Broderick JP. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002; 33: 2631-2635.
20 Giudetti B, Spallone A. The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms. Surg Neurol 1981; 15: 239-248.
21 Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the An-Ticoagulation and Risk Factors inAtrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
22 Hanley DF. Intraventrikuläre Anwendung von Thromolytika. In: Schneider D, Schwab S, Hacke W. (Hrsg). Kontroversen in der Neurointensivmedizin. Stuttgart, New York: Georg Thieme Verlag; 2005
23 Hijdra A, van Gijn J, Nagelkerke NJ, Vermeulen M, van Crevel H. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke 1988; 19: 1250-1256.
24 Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurismal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 2002; 97: 771-778.
25 Hoffman M, Monroe 3rd DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-695.
26 Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Jüttler E, Wikner J, Müller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Stroke 2006; 37: 1465-1470.
27 Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, Du XL, Bao QJ. Incidence and trend of stroke and its subtypes in China: results from three large cities. Stroke 2006; 37: 63-68.
28 Juvela S, Heiskanen O, Poranen A, Valtonen S, Kuurne T, Kaste M, Troupp H. The treatment of spontaneous intracerebral hemorrhage. A prospective randomized trial of surgical and conservative treatment. J Neurosurg 1989; 70: 755-758.
29 Kassell NF, Haley EC, Torner JC. Antifibrinolytic therapy in the treatment of aneurysmal subarachnoid hemorrhage. Clin Neurosurg 1986; 33: 137-145.
30 Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 1996; 27: 1783-1787.
31 Labovitz DL, Halim A, Boden-Albala B, Hauser WA, Sacco RL. The incidence of deep and lobar intracerebral hemorrhage in whites, blacks, and Hispanics. Neurology 2005; 23: 518-522.
32 Lee KR, Kawai N, Kim S, Sagher O, Hoff JT. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival ina rat model. J Neurosurg 1997; 86: 272-278.
33 Leira EC, Acharya AB, Cruz-Flores S, Albaker OJ, Rao VK, Abdulrauf SI. Blood pressure surge precedes intracerebral hemorrhage. Neurocrit Care 2005; 02: 43-45.
34 Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, Castillo J. Stroke Project, Cerebrocascular Diseases Group of the Spanish Neurological Society. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004; 63: 461-467.
35 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-253.
36 Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777-785.
37 Mayer SA, Brun N, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Europe/AustralAsia-NovoSeven ICH Trial Investigators. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36: 74-79.
38 Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol 2005; 04: 662-672.
39 McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracererbal haemorrhage. Lancet Neurol 2004; 03: 484-492.
40 Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH, STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 9457: 387-397.
41 Mendelow AD. More conclusions from the International Surgical Trial in Intracerebral Haemorrhage (STICH). European Stroke Conference (ESC). Bologna: Virtual Stroke University. 27.5.2005 http://stroke- university.com/view
42 Morgenstern LB, Frankowski RF, Shedden P, Pasteur W, Grotta JC. Surgical treatment for intracerebral hemorrhage (STICH): a single-center, randomized clinical trial. Neurology 1998; 51: 1359-1363.
43 NINDS ICH Workshop Participants. Priorities for clinical research in intracerebral hemorrhage. Report from a National Institute of Neurologic Disorders and Stroke Workshop. Stroke 2005; 36: e23-e41.
44 O´Donell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, Ikeda D, Greenberg SM. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342: 240-245.
45 Palmer JD, Francis JL, Pickard JD, Iannotti F. The efficacy and safety of aprotinin for hemostasis during intracranial surgery. J Neurosurg 2003; 98: 1208-1216.
46 Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003; 53: 3-39.
47 Passero S, Ciacci G, Ulivelli M. The influence of diabetes and hyperglycemia on clinical course after intracerebral hemorrhage. Neurology 2003; 61: 1351-1356.
48 Piriyawat P, Morgenstern LB, Yawn D, Hall CE, Grotta JC. Treatment of acute intracerebral hemorrhage with e-aminocaproic acid ±a pilot study. Neurocrit Care 2004; 01: 47-51.
49 Prasad K, Shrivastava A. Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev. 2000: CD000200.
50 Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344: 1450-1460.
51 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
52 Ritter MA, Droste DW, Hegedus K, Szepesi R, Nabavi DG, Csiba L, Ringelstein EB. Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology 2005; 64: 1233-1237.
53 Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology 2003; 54: 77-82.
54 Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880-884.
55 Steiner T, Diringer M, Rosand J. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and open questions. Stroke 2006; 37: 256-262.
56 Steiner T, Diringer MN, Schneider D, Mayer SA, Begtrup K, Broderick J, Skolnick BE, Davis SM. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery 2006; 59: 767-774.
57 Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997; 28: 491-499.
58 Teernstra OP, Evers SM, Lodder J, Leffers P, Franke CL, Blaauw G. Multicenter randomized controlled trial (SICHPA). Stroke 2003; 34: 968-974.
59 Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk factors for cerebral hemorrhage in the era of wellcontrolled hypertension. Melbourne Risk Factor Study (MERFS) Group. Stroke 1996; 27: 2020-2025.
60 Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med 1999; 27: 617-621.
61 von Baumgarten FJ, Burkhard G, Englert D, Kraus P, Mertens HG, Muller-Berghaus G, Przuntek H. Local hemostasis in subarachnoid hemorrhage. Eur Neurol 1987; 27: 149-154.
62 Vujkovac B, Sabovic M. Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid. Nephrol Dial Transplant 2000; 15: 107-109.
63 Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauterbach KW, Diener HC. German Stroke Data Bank Collaborators. Management patterns and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis 2003; 15: 29-36.
64 Wijdicks EF, Hasan D, Lindsay KW, Brouwers PJ, Hatfield R, Murray GD, van Gijn J, Vermeulen M. Short-term tranexamic acid in aneurismal subarachnoid hemorrhage. Stroke 1989; 20: 1674-1679.
65 Xi G, Fewel ME, Hua Y, Thompson BGJr, Hoff JT, Keep RF. Intracerebral hemorrhage: pathophysiology and therapy. Neurocrit Care 2004; 01: 5-18.
66 Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003; 89: 278-283.
67 Zuccarello M, Brott T, Derex L, Kothari R, Sauerbeck L, Tew J, van Loveren H, Yeh HS, Tomsick T, Pancioli A, Khoury J, Broderick J. Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study. Stroke 1999; 30: 1833-1839.